AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Mefenamic acid is primarily used to alleviate mild to moderate pain, including menstrual pain (dysmenorrhea), headache, dental pain, muscular pain, and pain due to various medical conditions.
Anti-inflammatory Effects: Like other NSAIDs, mefenamic acid works by inhibiting the production of prostaglandins, which are substances in the body that contribute to inflammation. By reducing inflammation, mefenamic acid helps relieve pain and swelling associated with inflammatory conditions such as arthritis.
Fever Reduction: Mefenamic acid can also help reduce fever by acting on the hypothalamic heat-regulating center in the brain.
Menstrual Pain Relief: Mefenamic acid is particularly effective in relieving menstrual pain and associated symptoms, such as abdominal cramps, back pain, and pelvic discomfort.
Arthritis Management: It can be used in the management of various types of arthritis, including osteoarthritis and rheumatoid arthritis, to reduce pain, inflammation, and stiffness in the joints.
Musculoskeletal Disorders: Mefenamic acid may be prescribed for other musculoskeletal disorders, such as tendonitis, bursitis, and sprains, to help alleviate pain and inflammation.
Dental Pain: It is also used for the relief of dental pain, including toothache and post-dental procedure discomfort.
Migraine: In some cases, mefenamic acid may be used to alleviate the pain associated with migraine headaches.
Gastrointestinal Side Effects: Despite its effectiveness, mefenamic acid, like other NSAIDs, can cause gastrointestinal side effects such as stomach pain, nausea, indigestion, heartburn, and diarrhea. Long-term use or high doses of mefenamic acid may increase the risk of gastrointestinal ulcers and bleeding.
Cardiovascular Risk: NSAIDs, including mefenamic acid, may slightly increase the risk of cardiovascular events such as heart attack and stroke, particularly in individuals with pre-existing cardiovascular conditions or those taking high doses for prolonged periods.
Renal Effects: Prolonged use of NSAIDs like mefenamic acid can potentially lead to kidney damage or worsen pre-existing kidney conditions, especially in susceptible individuals.
Allergic Reactions: Some individuals may experience allergic reactions to mefenamic acid, which can manifest as rash, itching, swelling of the face or throat, and difficulty breathing. Allergic reactions require immediate medical attention.
Liver Toxicity: Rarely, mefenamic acid can cause liver toxicity, characterized by symptoms such as yellowing of the skin or eyes (jaundice), dark urine, abdominal pain, and unusual fatigue. Patients experiencing these symptoms should seek medical help promptly.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 3.3 | 0.9 | 2.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.9 | 0.7 | 1.71 |
| Allergies | 3.7 | 1.6 | 1.31 |
| Allergy to milk products | 1.1 | 1 | 0.1 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 4.4 | 3.7 | 0.19 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.5 | 2.6 |
| Ankylosing spondylitis | 1.9 | 1.5 | 0.27 |
| Anorexia Nervosa | 1.3 | 2.4 | -0.85 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 3 | 2 | 0.5 |
| Atherosclerosis | 1.8 | 1.2 | 0.5 |
| Atrial fibrillation | 2.8 | 1.3 | 1.15 |
| Autism | 5.7 | 5.2 | 0.1 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 1.6 | 1.7 | -0.06 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.9 | 0.3 | 2 |
| Cancer (General) | 0.9 | 0.3 | 2 |
| Carcinoma | 3.1 | 1.6 | 0.94 |
| Celiac Disease | 1.9 | 2.3 | -0.21 |
| Cerebral Palsy | 1.3 | 1.1 | 0.18 |
| Chronic Fatigue Syndrome | 3.3 | 3.5 | -0.06 |
| Chronic Kidney Disease | 2.7 | 1.2 | 1.25 |
| Chronic Lyme | 0.5 | 0.8 | -0.6 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.7 | -0.31 |
| Chronic Urticaria (Hives) | 0.6 | 0.9 | -0.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.1 | -0.57 |
| Cognitive Function | 2.1 | 1.4 | 0.5 |
| Colorectal Cancer | 5.9 | 1.1 | 4.36 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 1.2 | 2.3 | -0.92 |
| COVID-19 | 4.9 | 5.5 | -0.12 |
| Crohn's Disease | 6.2 | 3.7 | 0.68 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.1 | -1.1 | |
| deep vein thrombosis | 2.3 | 1.4 | 0.64 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 5.9 | 4.5 | 0.31 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 1.3 | 0.08 |
| Endometriosis | 1.6 | 1.7 | -0.06 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 1.9 | 2 | -0.05 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 2.2 | 0.7 | 2.14 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 3.1 | 0.16 |
| gallstone disease (gsd) | 2.2 | 1.2 | 0.83 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.3 | 4.33 |
| Generalized anxiety disorder | 2.1 | 1.8 | 0.17 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.7 | 1.14 |
| Graves' disease | 1.6 | 2.3 | -0.44 |
| Gulf War Syndrome | 0.6 | 1.9 | -2.17 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 2.7 | 1 | 1.7 |
| Heart Failure | 3.1 | 1.2 | 1.58 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.5 | 0.6 | -0.2 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.2 | 0.5 |
| hyperglycemia | 0.7 | 1.3 | -0.86 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.7 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.6 | 4 | -0.54 |
| Hypothyroidism | 0.1 | 0.9 | -8 |
| Hypoxia | 1.1 | 0.3 | 2.67 |
| IgA nephropathy (IgAN) | 1.9 | 3 | -0.58 |
| Inflammatory Bowel Disease | 5.8 | 4.7 | 0.23 |
| Insomnia | 1.2 | 2 | -0.67 |
| Intelligence | 0.6 | 0 | 0 |
| Intracranial aneurysms | 1.3 | 0.6 | 1.17 |
| Irritable Bowel Syndrome | 4.9 | 3.6 | 0.36 |
| ischemic stroke | 2 | 0.8 | 1.5 |
| Liver Cirrhosis | 4.8 | 3.8 | 0.26 |
| Long COVID | 4.1 | 3.8 | 0.08 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 0.5 | 0.2 |
| Mast Cell Issues / mastitis | 0.7 | 0.9 | -0.29 |
| ME/CFS with IBS | 0.3 | 0.6 | -1 |
| ME/CFS without IBS | 1.2 | 1.2 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.7 | 0.29 |
| Metabolic Syndrome | 5.3 | 4.6 | 0.15 |
| Mood Disorders | 6.2 | 4 | 0.55 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
| Multiple Sclerosis | 2.6 | 3.7 | -0.42 |
| Multiple system atrophy (MSA) | 0.3 | 0.6 | -1 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 1.8 | -5 |
| Neuropathy (all types) | 0.7 | 1.4 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2.3 | 0.13 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.6 | 0.83 |
| Obesity | 6.2 | 5.9 | 0.05 |
| obsessive-compulsive disorder | 3.1 | 2.3 | 0.35 |
| Osteoarthritis | 1.2 | 1.3 | -0.08 |
| Osteoporosis | 1.7 | 0.8 | 1.13 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 5.2 | 3.4 | 0.53 |
| Polycystic ovary syndrome | 5.2 | 2.4 | 1.17 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.6 | 0.6 | 0 |
| Primary sclerosing cholangitis | 1.7 | 2.2 | -0.29 |
| Psoriasis | 1.9 | 2.4 | -0.26 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 2.9 | 0.41 |
| Rosacea | 0.6 | 0.8 | -0.33 |
| Schizophrenia | 3.6 | 2.5 | 0.44 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 1.4 | 1 | 0.4 |
| Sleep Apnea | 1.2 | 1.7 | -0.42 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
| Stress / posttraumatic stress disorder | 1.9 | 2.1 | -0.11 |
| Systemic Lupus Erythematosus | 4 | 1.4 | 1.86 |
| Tic Disorder | 0.9 | 0.3 | 2 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3.2 | 1.7 | 0.88 |
| Type 2 Diabetes | 5.2 | 4.6 | 0.13 |
| Ulcerative colitis | 2.6 | 5.5 | -1.12 |
| Unhealthy Ageing | 4.1 | 1.9 | 1.16 |
| Vitiligo | 2.2 | 0.9 | 1.44 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
